Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury
Open accessThe DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index; 13 of the 35 sources its claims cite were checked for support.
Abstract
Drug-induced liver injury (DILI) continues to be a major source of clinical attrition, precautionary warnings, and post-market withdrawal of drugs. Accordingly, there is a need for more predictive tools to assess hepatotoxicity risk in drug discovery. Three-dimensional (3D) spheroid hepatic cultures have emerged as promising tools to assess mechanisms of hepatotoxicity, as they demonstrate enhanced liver phenotype, metabolic activity, and stability in culture not attainable with conventional two-dimensional hepatic models. Increased sensitivity of these models to drug-induced cytotoxicity has been demonstrated with relatively small panels of hepatotoxicants. However, a comprehensive evaluation of these models is lacking. Here, the predictive value of 3D human liver microtissues (hLiMT) to identify known hepatotoxicants using a panel of 110 drugs with and without clinical DILI has been assessed in comparison to plated two-dimensional primary human hepatocytes (PHH). Compounds were treated long-term (14 days) in hLiMT and acutely (2 days) in PHH to assess drug-induced cytotoxicity over an 8-point concentration range to generate IC 50 values. Regardless of comparing IC 50 values or exposure-corrected margin of safety values, hLiMT demonstrated increased sensitivity in identifying known hepatotoxicants than PHH, while specificity was consistent across both assays. In addition, hLiMT out performed PHH in correctly classifying hepatotoxicants from different pharmacological classes of molecules. The hLiMT demonstrated sufficient capability to warrant exploratory liver injury biomarker investigation (miR-122, HMGB1, α -GST) in the cell-culture media. Taken together, this study represents the most comprehensive evaluation of 3D spheroid hepatic cultures up to now and supports their utility for hepatotoxicity risk assessment in drug discovery.
Overview
CoChat Summary
TL;DR
In a 110-drug retrospective panel, 3D human liver microtissues (hLiMT) detected more cytotoxicity IC50 values and showed greater sensitivity than plated 2D primary human hepatocytes (PHH) for identifying clinical DILI-positive compounds, with similar specificity. The hLiMT model also supported exploratory liver-injury biomarker measurement in culture supernatant.
Key findings
- hLiMT detected more IC50 values than PHH across the 110-drug set: 56/110 vs 40/110. Among DILI-positive compounds, no IC50 was determined for 33% (23/69) in hLiMT vs 54% (37/69) in PHH.
- At fixed IC50 thresholds, hLiMT sensitivity was higher at every threshold: at 10 μM, 18.8% (13/69) vs 4.3% (3/69); at 100 μM, 60.9% (42/69) vs 33.3% (23/69). Specificity at 100 μM was 85.4% for both assays; PLR was 4.16 for hLiMT vs 2.28 for PHH, and NLR was 0.46 vs 0.78.
- Using margin-of-safety (MOS = IC50/total plasma Cmax) thresholds, hLiMT again showed higher sensitivity: at 10× MOS, 36.2% (25/69) vs 20.3% (14/69), with specificity 97.6% for both and PLR 14.86 vs 8.32. At 100× MOS, sensitivity was 59.4% vs 40.6%, with specificity 80.5% vs 85.4%.
- hLiMT better distinguished some structurally related pairs: bosentan and sitaxsentan had MOS values of 12.5× and 8.7×, while ambrisentan was not detected; PHH detected no IC50 for any of the three endothelin-receptor antagonists. Exploratory biomarkers α-GST, HMGB1, and miR-122 were measurable in hLiMT supernatant after chlorpromazine exposure.
Methods
- A panel of 110 marketed drugs was classified into five DILI severity categories; categories 1–3 were considered DILI-positive (69 drugs) and categories 4–5 DILI-negative (41 drugs).
- Cytotoxicity was assessed by ATP-based CellTiter-Glo: plated 2D PHH were treated for 48 h, while 3D hLiMT (primary human hepatocytes co-cultured with non-parenchymal cells) were treated for 14 days with re-dosing; IC50 values were generated over an 8-point concentration range and exposure-corrected MOS values were calculated using total plasma Cmax.
- Predictive performance was evaluated with ROC analysis, fixed IC50 and MOS thresholds, Cohen’s kappa, and positive/negative likelihood ratios; reproducibility was tested across different NPC and hepatocyte lots, and exploratory biomarkers were measured in hLiMT culture media.
Limitations
- The paper states that hLiMT failed to properly classify approximately 40% of DILI-positive compounds; no cytotoxicity was observed for 23/69 DILI-positive drugs, and 28/69 DILI-positive compounds fell above a 100× MOS threshold. Many misclassified compounds were associated with low-incidence or idiosyncratic DILI.
- The paper notes that the hLiMT spheroids contain only approximately 1000 cells, which could limit sensitivity for secondary supernatant endpoints, although exploratory biomarkers were detected. It also states that it remained unclear whether enhanced predictive value was due to culture complexity, treatment duration, or other factors.
- Evident from the text: the ROC comparison using only compounds with IC50 values was biased by the different numbers of IC50 values obtained between assays, so the authors relied on fixed practical thresholds; these thresholds are somewhat arbitrary and assay performance depended on the compound set and concentration ranges achievable in vitro.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
9 Valid · 1 Not valid · 15 Not checked · 80 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Increased sensitivity of these models to drug-induced cytotoxicity has been demonstrated with relatively small panels of hepatotoxicants.”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Abstract
What the sources say
- Supportedcites Bell et al. 2016 matched to “Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease” (2016) source
The Discussion reports that long-term dosing enhanced the sensitivity of PHH spheroids to a panel of five hepatotoxins. The Results likewise report increased toxicity and lower EC50 values after prolonged exposure for all five compounds. (LLM, conf=0.93)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“These data are in agreement with the findings of Bell et al. (2016) who noted prolonged drug exposure of up to 28 days resulted in increased sensitivity for detection of DILI compounds amiodarone, bosentan, diclofenac, fialuridine, and tolcapone (Bell et al. 2016).”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Discussion
What the sources say
- Supportedcites Bell et al. 2016 matched to “Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease” (2016) source
The Results section (‘PHH spheroids are a suitable system to study chronic DILI’) reports testing all five named compounds after 48 hours, 8 days, and 28 days; prolonged exposure increased toxicity and reduced EC50 values for all five. The Discussion likewise describes enhanced sensitivity with long-term dosing. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In addition, the potential of the 3D hLiMT to report on the release of novel translational in vivo liver hepatotoxicity biomarkers, miR-122, a highly liver specific microRNA (Wang et al. 2009), HMGB1, a marker of immune modulation and necrosis (Antoine et al. 2009), and α-GST, a sensitive, highly specific and early biomarker for hepatocellular injury (Muller and Dieterle 2009), following exposure”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Discussion
What the sources say
- Supportedcites Wang et al. 2009 matched to “Circulating microRNAs, potential biomarkers for drug-induced liver injury” (2009) source
The citation is attached specifically to the description of miR-122 as a highly liver-specific microRNA, not to the claim about the 3D hLiMT. The paper’s “Dose-and Duration-Dependent Changes on the Circulating miRNA” section says that miR-122 is highly restricted to the liver. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites Antoine et al. 2009 matched to “High-Mobility Group Box-1 Protein and Keratin-18, Circulating Serum Proteins Informative of Acetaminophen-Induced Necrosis and Apoptosis In Vivo” (2009) source
- Not checked — no full text of the sourcecites Muller and Dieterle 2009 matched to “Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring” (2009) source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Addition of extracellular bile acids in the cell-culture media caused increased cytotoxicity of liver spheroid cultures relative to normal media treated spheroid cultures treated with bosentan over 14 day (Hendriks et al. 2016).”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Discussion
What the sources say
- Supportedcites Hendriks et al. 2016 matched to “Hepatic 3D spheroid models for the detection and study of compounds with cholestatic liability” (2016) source
The Results section reports greater toxicity with bosentan plus bile acids than with bosentan alone in PHH and HepaRG spheroids. Its prolonged-exposure subsection says this synergistic toxicity was more pronounced after 14 days; the Discussion explicitly includes bosentan among the compounds tested over that period. The indexed passages provide no page numbers. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Based on the optimized thresholds for both IC50 and MOS values, both PHH and hLiMT exhibited similar sensitivity for detection of known DILI causing drugs, with values between 63 and 72% (data not shown).”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing ROC assessments
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
55 more claims
Create a free account to see all 105 claims and every source verdict.
- It may state two separate claims as one. 32
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This was almost double the sensitivity of 3D hepatic spheroids for the same drug set (42%) based on previously published data31,47,48”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“a preclinical model that is currently widely used in pharma and was only able to correctly identify 8 out of the 19 toxic drugs in the set (Table 5).”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the toxicities of these 8 drugs have been shown to be poorly predicted by hepatic spheroids31,32.”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“whereas the 3D hepatic spheroids did (only 67% specificity)31”
From Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (2022) · cites this paper as [31]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Proctor et al. (Proctor et al., 2017) showed that liver microtissues combining hepatocytes with HSCs, Kupffer, and endothelial cells outperformed 2D systems (87% sensitivity, 92% specificity) and better reflected clinical DILI data.”
From A 3D bioengineered human liver for the study of acute and chronic drug-induced hepatotoxicity and fibrosis (2026) · cites this paper as Proctor et al., 2017
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Introduction
“Using drug-induced cytotoxicity as an endpoint, hLiMT assay experienced increased sensitivity and specificity to identify known human hepatotoxicants in relation to plated PHH.”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing practical fixed thresholds
“| 3D hLiMT IC50 [μM] | 69 | 41 | 13 | 38 | 3 | 56 | 10 | 18.8 | 92.7 | 2.57 | 0.88 | 0.091 | 0.097 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing practical fixed thresholds
“| 2D PHH IC50 [μM] | 69 | 41 | 23 | 35 | 6 | 46 | 100 | 33.3 | 85.4 | 2.28 | 0.78 | 0.176 | 0.014 |”
§ Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury > Results > Statistical analysis employing practical fixed thresholds
“| 2D PHH MOS (IC50/C max) | 69 | 41 | 23 | 35 | 6 | 46 | 50× | 33.3 | 85.4 | 2.28 | 0.78 | 0.156 | 0.031 |”
Citations
Cites
A Coefficient of Agreement for Nominal Scales
Cohen, J. (1960) · Educational and Psychological Measurement · doi:10.1177/001316446002000104 · Cited by 42,398 · cited 1×
“In addition, the concordance of each assay with known DILI status was assessed using Cohen’s Kappa (Cohen 1960).”
MethodConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 3×
“…etiologies that encompass DILI (Chalasani et al. 2008), with unknown factors driving patient susceptibility towards hepatic stress and injury (Chalasani and Bjornsson 2010), coupled with the poor concordance of preclinical species to identify human hepatotoxicants in vivo (Olson et al. 2000).”
BackgroundStatistics Notes: Diagnostic tests 2: predictive values
Altman, D. G., & Bland, J. M. (1994) · BMJ · doi:10.1136/bmj.309.6947.102 · Cited by 1,711
Diagnostic tests 4: likelihood ratios
Deeks, J. J., & Altman, D. G. (2004) · BMJ · doi:10.1136/bmj.329.7458.168 · Cited by 1,600 · cited 1×
“In addition, these parameters can be calculated directly from sensitivity and specificity estimates for tests that have binary results (Altman and Bland 1994a; Deeks and Altman 2004).”
BackgroundGodoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280 · cited 1×
“In most cases, these systems displayed enhanced metabolic activity, hepatocellular phenotype, and stability in culture, previously not attainable with traditional hepatic cell line or hepatocyte models [refer to review (Godoy et al. 2013)].”
BackgroundSelf-citationMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219 · cited 4×
“…demonstrated increased CYP450 activity and improved stability of liver phenotype over time in culture compared to monocultures of primary hepatocytes (Khetani and Bhatia 2008), which was hypothesized to be driving in part the increased sensitivity towards hepatotoxicants (Khetani et al. 2013).”
BackgroundInfluentialCirculating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149 · cited 2×
“In addition, the potential of the 3D hLiMT to report on the release of novel translational in vivo liver hepatotoxicity biomarkers, miR-122, a highly liver specific microRNA (Wang et al. 2009), HMGB1, a marker of immune modulation and necrosis (Antoine et al.”
BackgroundDeterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting
Ma, X., Qu, X., Zhu, W., Li, Y.-S., Yuan, S., Zhang, H., Liu, J., Wang, P., Lai, C. S. E., Zanella, F., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524510113 · Cited by 872 · cited 1×
“…fibroblasts (Khetani and Bhatia 2008; Khetani et al. 2013), three-dimensional (3D) bioprinted liver tissues comprised of several hepatic cell types (Ma et al. 2016; Nguyen et al. 2016), and 3D spheroid cultures either as mono-culture or co-culture with hepatic non-parenchymal cells (NPC) (Bell et…”
BackgroundChalasani, N., Fontana, R. J., Bonkovsky, H. L., Watkins, P. B., Davern, T., Serrano, J., Yang, H., & Rochon, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.011 · Cited by 755 · cited 3×
“This is not surprising in that DILI is comprised of many different etiologies and mechanisms, including factors that are both compound- and patient-related (Chalasani and Bjornsson 2010; Chalasani et al. 2008).”
BackgroundBell, C. C., Hendriks, D. F. G., Moro, S. M. L., Ellis, E., Walsh, J., Renblom, A., Fredriksson Puigvert, L., Dankers, A. C. A., Jacobs, F., Snoeys, J., et al. (2016) · Scientific Reports · doi:10.1038/srep25187 · Cited by 739 · cited 16×
“2016), and 3D spheroid cultures either as mono-culture or co-culture with hepatic non-parenchymal cells (NPC) (Bell et al. 2016; Messner et al. 2013).”
BackgroundResultInfluential
Cited by
Items 201–300 of 327
Lubamba, B., Jensen, T. C., & McClelland, R. (2022) · Applied Sciences · doi:10.3390/app12062786 · Cited by 7
MatriGrid® Based Biological Morphologies: Tools for 3D Cell Culturing
Mai, P., Hampl, J., Baca, M., Brauer, D., Singh, S., Weise, F., Borowiec, J., Schmidt, A., Küstner, M., Klett, M., et al. (2022) · Bioengineering · doi:10.3390/bioengineering9050220 · Cited by 11
“The acceptance of organotypic 3D models ranges up to millifluidic scale systems [54,55], whereby most systems are based on static, passive fluidics [53,56,57].”
BackgroundDesign and engineering of multiorgan systems
Renggli, K., & Frey, O. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817202-5.00012-7 · Cited by 8
Novel advances in biotransformation and bioactivation research – 2020 year in review
Khojasteh, S. C., Argikar, U. A., Driscoll, J. P., Heck, C. J. S., King, L. M., Jackson, K. D., Jian, W., Kalgutkar, A. S. S., Miller, G. P., Kramlinger, V. M., et al. (2021) · Drug Metabolism Reviews · doi:10.1080/03602532.2021.1916028 · Cited by 8
Liver-Chip: Reproducing Human and Cross-Species ToxicitiesPreprint
Jang, K., Otieno, M. A., Ronxhi, J., Lim, H., Ewart, L. C., Kodella, K. R., Petrópolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/631002 · Cited by 7
Self-citationHutchings, M., Korfi, K., Montesinos, P., Santoro, A., Hou, H., Martínez‐Sánchez, P., Vives, S., Galimberti, S., Chen, T., Frigeni, M., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100110 · Cited by 11
“18 In part B, fi xed doses from 1 mg to 4 mg IV every 3 weeks were tested, followed by single step-up (SSU) and then double step-up (DSU) regimens with doses of up to 18 mg (supplemental Figure 2A-B).”
Negi, C. K., Sakolish, C., Tsai, H.-H. D., Nitsche, K. S., Gang, H., Bajaj, P., Ferguson, S., Stanko, J. P., Hewitt, P. G., Kukla, D. A., et al. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00554 · Cited by 7
Nah, H., Michell, A. R., Rogy, K. M., Lally, O. J., & Khetani, S. R. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115737 · Cited by 11
Cavaco, M. C., Pérez‐Peinado, C., Valle, J., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116573 · Cited by 6
Evaluation of dioxin induced transcriptomic responses in a 3D human liver microtissue model
Yan, L., Messner, C. J., Tian, M., Gou, X., Suter‐Dick, L., & Zhang, X. (2022) · Environmental Research · doi:10.1016/j.envres.2022.112906 · Cited by 7
The native liver as inspiration to create superior in vitro hepatic models
Carpentier, N., Urbani, L., Dubruel, P., & Vlierberghe, S. V. (2023) · Biomaterials Science · doi:10.1039/d2bm01646j · Cited by 7
Engineered Human Liver Cocultures for Investigating Drug-Induced Liver Injury
Monckton, C. P., & Khetani, S. R. (2018) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-7677-5_11 · Cited by 6
Chemical Probes for drug-induced Liver Injury Imaging
Tao, J., Rong, P., & Wang, W. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0330 · Cited by 7
Novel Perspectives of Stem Cell Manufacturing and Therapies
Kitala, D., & Maurício, A. C. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.82986 · Cited by 6
Jeong, C. G., Negro, G. D., Getsios, S., & Ekert, J. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813671-3.00005-0 · Cited by 13
Advances in the Application of In Silico ADMET Models – An Industry Perspective
Wang, W., Melnikov, F., Napoli, J., & Desai, P. V. (2024) · Wiley eBooks · doi:10.1002/9783527840748.ch21 · Cited by 8
Multi-organ model assessment of neurotoxicity following exposure of liver spheroids to drugs
Wu, W., Anas, F., Koc, B., Tian, L., Hasselkus, R., Rezania, D., Sharareh, S., Farberov, L., Zlotnik, D., Alon, A., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118021 · Cited by 5
Liu, X., Higuchi, Y., Sakamoto, Y., Yanagida, S., Uehara, S., Suemizu, H., Kanda, Y., & Kawagishi, H. (2025) · Journal of Applied Toxicology · doi:10.1002/jat.4863 · Cited by 5
Yeisley, D. J., Ren, L., Papineau, K. S., Schnackenberg, L. K., da Costa, G. G., Patterson, T. A., Fitzpatrick, S. C., & Shi, Q. (2025) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2025.102199 · Cited by 9
“…PHLSs technology showed that treatments for 28 days remarkably increased the toxicity of certain test drugs as compared to sandwich cultured PHH [35], subacute exposure to 6PPD or 6PPD-Q in PHLSs over 28 days did not demonstrate greater functional alterations compared to the sandwich cultured…”
Integration of in vitro and in silico approaches enables prediction of drug-induced liver injury
Geci, R., Sayin, A. Z., Schaller, S., & Kuepfer, L. (2026) · Archives of Toxicology · doi:10.1007/s00204-026-04305-2 · Cited by 7
Ingelman‐Sundberg, M., & Lauschke, V. M. (2024) · Drug Metabolism and Disposition · doi:10.1124/dmd.123.001302 · Cited by 7
3D-Bioprinted Hepar-on-a-Chip Implanted in Graphene-Based Plasmonic Sensors
Wang, Y., Ma, D., Zhang, Q., Qian, W., Liang, D., Shen, J., Pan, X., Wang, C., Sheng, E., & Zhu, D. (2024) · ACS Sensors · doi:10.1021/acssensors.4c00833 · Cited by 7
Qian, W., Gong, G., Su, H., Zhao, Y., Fu, W., Wang, Y., Ji, W., Sun, X., Zhang, B., Ma, L., et al. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.02.021 · Cited by 6
Decellularized Mouse Liver as a Small-Scale Scaffold for the Creation of a Miniaturized Human Liver
Ijima, H., Fukuda, Y., Uehara, M., Shafiq, M., Wu, F., Cho, J., Sakai, Y., Miyata, T., Yamao, T., Nakao, Y., et al. (2023) · JOURNAL OF CHEMICAL ENGINEERING OF JAPAN · doi:10.1080/00219592.2023.2204899 · Cited by 8
Borgström, A., Filippi, B. G. H., Hewitt, P. G., Wolf, A., & Gebauer, M. (2023) · Applied In Vitro Toxicology · doi:10.1089/aivt.2023.0004 · Cited by 4
“22 In this study, the exosomal miRNA response of hepatic spheroids to toxic concentrations of Chlorpromazine was analyzed.”
Cell sources and methods for producing organotypic in vitro human tissue models
Hayden, P. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817202-5.00002-4 · Cited by 11
Stulpinas, A., Imbrasaitė, A., Krestnikova, N., & Kalvelytė, A. V. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89395 · Cited by 9
“3D hepatocyte spheroids (named as human liver microtissues) have demonstrated better prediction of liver toxicity than two-dimensional primary human hepatocytes model [191].”
BackgroundSafety Assessment of Pharmaceuticals
Kenna, J. G., & Ram, R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813697-3.00020-2 · Cited by 6
Dara, L., & Kaplowitz, N. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch54 · Cited by 8
Tang, Y., Lu, S., Liang, W., He, Y., Hao, J., Xu, W., Sun, Y., & Zhan, C. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114465 · Cited by 10
Lenich, A., Alsdorf, S., & Ruez, S. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100230 · Cited by 6
Physiologically relevant microsystems to study viral infection in the human liver
McDuffie, D., Barr, D., Agarwal, A., & Thomas, E. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.999366 · Cited by 4
“This technique has been commercialized by InSphero and is also applicable to organoid co-cultures (Messner et al., 2013, 2018; Proctor et al., 2017).”
MethodProteomic workflows for deep phenotypic profiling of 3D organotypic liver models
Koutsilieri, S., Mickols, E., Végvári, Á., & Lauschke, V. M. (2024) · Biotechnology Journal · doi:10.1002/biot.202300684 · Cited by 4
“[11,12] Hepatic spheroids can more-over reliably predict liver toxicity, [13,14] CYP induction [15] and hepatic clearance [16,17] and have been used as relevant models of liver diseases, such as metabolic dysfunction-associated steatotic liver disease (MASLD).”
MethodBahtiri, S., Hagens, T. M. S., van de Water, B., & Niemeijer, M. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2516051 · Cited by 3
Advanced human liver models for the assessment of drug-induced liver injury
Mun, S. J., Lee, J., Shin, Y., & Son, M. J. (2022) · Organoid · doi:10.51335/organoid.2022.2.e17 · Cited by 4
Engineering a three-dimensional liver steatosis model
Johnston, E. K., Zhou, F., Soto–Gutiérrez, A., Taner, C. B., Cook, K. E., Liu, Y., & Abbott, R. D. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167888 · Cited by 4
Ali, A. S. M., Wu, D., Roehrs, V., Nguyen, D. B. T., Ziersch, M., Braeuning, A., & Kurreck, J. (2025) · Biofabrication · doi:10.1088/1758-5090/ae1063 · Cited by 6
“Drugs with MOS 100 were considered potentially hepatotoxic in vitro [30, 31] and based on the best prediction accuracy at different MOS cutoffs (table S2), as a 100-fold difference between in vitro IC 50 and clinical plasma concentrations provides a safety margin that minimizes false negatives in…”
Highlight report: prediction of drug induced liver injury (DILI) with human hepatocytes in vitro
Albrecht, W. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2132-5 · Cited by 3
“Using the DILI severity category and exposure-corrected cytotoxicity, the authors report that hepatocyte spheroids can be used for classifying hepatotoxicants from different pharmacological classes (Proctor et al. 2017).”
BackgroundMethodInfluentialNeed for alternative testing methods and opportunities for organ-on-a-chip systems
Wilkinson, J. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-817202-5.00001-2 · Cited by 7
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
Novac, O., Silva, R., Young, L.-M., Lachani, K., Hughes, D., & Kostrzewski, T. M. (2022) · Journal of Visualized Experiments · doi:10.3791/63389-v · Cited by 20
Rana, P., Khan, S., Arat, S., Potter, D., & Khan, N. (2022) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.2c00243 · Cited by 3
Bajaj, P., Brennan, R., Laurent, S., Sauzeat, S., Dufault, M. R., Richards, B., & Adkins, K. (2025) · Toxicological Sciences · doi:10.1093/toxsci/kfaf012 · Cited by 5
Olubamiwa, A. O., Ma, J., Dehanne, P., Noban, C., Angın, Y., Barberan, O., & Chen, M. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2514537 · Cited by 3
Serras, A. S., Cipriano, M., Silva, P. M. D. G., & Miranda, J. P. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.91794 · Cited by 5
Taute, F., Homs-Corbera, A., & Gaudriault, P. (2021) · Open Research Europe · doi:10.12688/openreseurope.13335.1 · Cited by 3
Opportunities for microphysiological systems from the view of Japanese industries
Naraoka, H., Iguchi, T., Harada, K., Usui, T., Suwa, Y., Ando, M., Sakura, T., & Ohkubo, T. (2024) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2024.101034 · Cited by 2
Bila, N. M., Vaso, C. O., Belizário, J. A., de Assis, L. R., Regasini, L. O., Fontana, C. R., Fusco‐Almeida, A. M., Costa-Orlandi, C. B., & Mendes‐Giannini, M. J. S. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121523 · Cited by 1
“This sensitivity of cultures may be attributed to varying levels of perfusion of photosensitizers, oxygen, and the expression of genes and proteins [25,34,40,41].”
Sakatis, M. Z., Norona, L. M., Karmel, J., Proctor, W. R., Sarr, F. H., Rana, P., Zane, D., Rae, J. M. C., Faber, S. C., Ravindra, K. C., et al. (2025) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5c00235 · Cited by 2
Self-citationNon-invasive quantification of viability in liver spheroids using deep learning
Dubinsky, D., Harel, S., Bein, A., Nyska, A., Ya’ari, S., Koc, B., Anas, F., Bentwich, I., & Wolf, L. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1797474 · Cited by 6
“To predict potential DILI, cell culture viability assessment is widely employed in drug safety evaluations (Bell et al., 2016; Novac et al., 2022; Ewart et al., 2022; Proctor et al., 2017).”
InfluentialLi, Y., Sheng, H., Zhou, T., Xing, C., Kukasch, M., Shao, S., Youhanna, S. C., Vorrink, S. U., Liang, Y., Nies, A. T., et al. (2026) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2026.100346 · Cited by 3
Horn, G., Frielingsdorf, F., Demel, T., Rothmiller, S., Worek, F., & Amend, N. (2024) · Journal of Applied Toxicology · doi:10.1002/jat.4694 · Cited by 3
“It is difficult to explain why a decrease of the EC 50 values indicating increasing cytotoxicity (Bell et al., 2016; Gu et al., 2018; Proctor et al., 2017) was recorded in the course of VX exposure from 5 to 24 h but not after exposure to GF (Table 1).”
Dash, A., & Proctor, W. R. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813671-3.00006-2 · Cited by 4
Self-citationAutomated Analysis of Acetaminophen Toxicity on 3D HepaRG Cell Culture in Microbioreactor
Baca, M., Brauer, D., Klett, M., Fernekorn, U., Singh, S., Hampl, J., Groß, G. A., Mai, P., Friedel, K., & Schober, A. (2022) · Bioengineering · doi:10.3390/bioengineering9050196 · Cited by 4
Perspective on In Vitro Liver Toxicity Models
Witek, R. P., & Bonzo, J. A. (2018) · Applied In Vitro Toxicology · doi:10.1089/aivt.2018.29017.wit · Cited by 2
A microvascularized in vitro liver model for disease modeling and drug discoveryPreprint
Bonanini, F., Dinkelberg, R., Torregrosa, M. C., Kortekaas, N., Hagens, T. M. S., Treillard, S., Kurek, D., van Duinen, V., Vulto, P., & Bircsak, K. M. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.05.602196 · Cited by 2
Bhattacharya, S., Singh, J., Gautam, R. K., Farooqui, N. A., Manocha, N., & Malhotra, H. (2025) · Wiley eBooks · doi:10.1002/9781394237654.ch9 · Cited by 2
Recent advances in multicellular human liver models
Mun, S. J., Lee, J., Shin, Y., Eun, V., Ji, Y., & Son, M. J. (2022) · Organoid · doi:10.51335/organoid.2022.2.e26 · Cited by 1
“PHHs/KCs Enhanced DILI sensitivity ∙ Easy to culture ∙ Structural complexity↓ [5]”
BackgroundInfluentialTran, A. T., Crawford, J. J., Mandal, D., Güney, T., & Karmel, J. (2023) · Medicinal chemistry reviews · doi:10.1021/mc-2023-vol58.ch19 · Cited by 1
Use of new approach methodology for hepatic safety assessment of covalent inhibitor drug candidates
Amberntsson, S., Foster, A. J., Chouhan, B., Wilkinson, S. D., Harlfinger, S., Smith, G., Kettle, J. G., Niedbala, M. J., Kavanagh, S. L., & Williams, D. P. (2025) · Toxicology Research · doi:10.1093/toxres/tfaf054 · Cited by 1
Self-citationHellgren, J., Chouhan, B., Uatay, A., Elgendy, R., Lindgren, J., Toki, N., Bonetti, A., Chaudhari, A., Pryde, K. R., Andersson, P. U., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01306-7 · Cited by 1
“ThesemetricsarecomparabletobinaryDILIpredictions obtainedfrombioactivityassayendpointsinPHHspheroids 28,61 , human liver microtissues 30 and liver chips 62,63 .”
Self-citationHartauer, M., Ho, H. S. S., Wan, M., Murphy, W. A., Tiley, J. B., Fallon, J. K., Bishop, C. E., & Brouwer, K. L. R. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05996-z · Cited by 2
“MHS have demonstrated significant utility in toxicity screen - ing applications [14 ] and identification of underlying drug toxicity [15] and disease [16, 17] mechanisms.”
Improving hepatic metabolic function with 3D iPSC-derived human hepatocytes
Garcia, V. P., Kiamehr, M., Versteegden, R., Naderlinger, E., Jennings, P., Verfaillie, C. M., Vos, J. C., & Moco, S. (2026) · Cell Biology and Toxicology · doi:10.1007/s10565-026-10203-1 · Cited by 1
“For further enhancement of 3D HLCs’ performance, immune components (Kupffer cells) could be integrated into the system to improve DILI predictivity (Proctor et al. 2017).”
Hellmold, D., Ziemianowicz, D. S., Ellermann, F., Depperschmidt, P., Appold, M., Omar, A. S., Kurz, J., Krieg-Schneider, F., Hoppe, T. P., Hackenberger, D., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-58939-4 · Cited by 1
Drees, A., Benfenati, E., Gadaleta, D., Gozalbes, R., de Lomana, M. G., Jiang, J., Maerten, A., Ortega-Vallbona, R., Serrano‐Candelas, E., Sanz-Serrano, J., et al. (2026) · Toxicology · doi:10.1016/j.tox.2026.154547 · Cited by 1
Translation of tissue-engineering innovations requires a connected ecosystem
Moisan, A., Kolesky, D. B., Miller, J. S., & Homan, K. A. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00111-y · Cited by 1
Karsten, R. E. H., Gier, K., de Meijer, V. E., Huibers, W. H. C., Permentier, H. P., Verpoorte, E. M. J., & Olinga, P. (2025) · Toxicology in Vitro · doi:10.1016/j.tiv.2025.106011 · Cited by 1
Toyoda, H., Nozue, A., Nishida, Y., Yakabe, Y., Aiki, Y., Ueyama-Toba, Y., Takayama, K., Mizuguchi, H., Mori, C., Torisawa, Y., et al. (2025) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2025.151497 · Cited by 1
Beers, J. L., Harvey, S. L., Geffert, R. M., Rushing, B. R., McRitchie, S., Sumner, S., & Jackson, K. D. (2025) · Toxicology in Vitro · doi:10.1016/j.tiv.2025.106126 · Cited by 3
Evaluation of Human Liver Microtissues for Drug Screening on Schistosoma mansoni Schistosomula
Lombardo, F. C., Ravaynia, P. S., Modena, M. M., Hierlemann, A. R., & Keiser, J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00614 · Cited by 1
“The multidonor (10) hLiMTs were purchased from Insphero AG (Schlieren, Switzerland).”
MethodDevelopment of small-scale fluidised bed bioreactor for 3D cell culture
da Silva, M., & Rafaela, J. (2020) · UCL Discovery (University College London) · Cited by 1
Restrepo, J. C. (2020) · Hepatología · doi:10.52784/27112330.118 · Cited by 1
Naito, Y., Yoshinouchi, Y., Sorayama, Y., Kohara, H., Kitano, S., Irie, S., & Matsusaki, M. (2021) · Acta Biomaterialia · doi:10.2139/ssrn.3906842 · Cited by 7
Łukasiak, M., Gatti, G., Chung, S., Kiloh, G., Robinson, C., Kasioulis, I., Gil, C., Panman, L., & Nikolaou, N. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.11.18.624145 · Cited by 4
Ferret-Miñana, A., Alcaraz, E., Horrillo, R., Ramón-Azcón, J., & De Chiara, F. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1798323
“Proctor et al. (Proctor et al., 2017) showed that liver microtissues combining hepatocytes with HSCs, Kupffer, and endothelial cells outperformed 2D systems (87% sensitivity, 92% specificity) and better reflected clinical DILI data.”
Regier, M. C., & Stevens, K. R. (2019) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012683-00253
In vitro primary human hepatocyte 3D spheroid model for hepatotoxicity studies
Li, F., Parikh, S., Cao, L., Cooper, K., & Zuo, R. (2019) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2018.09.134
Future perspectives of DILI prediction in vitro
Ghallab, A., & Seddek, A. (2019) · Archives of Toxicology · doi:10.1007/s00204-019-02530-6
Investigating Induced Pluripotent Stem Cells for Tissue Engineering and Hepatotoxicity Applications
Wills, L. R. (2019) · VTechWorks (Virginia Tech)
Microphysiological Systems (MPS) の医薬品安全性・毒性評価への応用と課題
Ishida, S. (2021) · doi:10.14982/rsmp.11.43 · Cited by 1
Wang, J., & Chen, E. (2021) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-1542-3_13
3D-Hunde-Lebersphäroide für die präklinische in vitro-Testung
Raić, A., Oberfrank, C., Birk, B., Class, R., & Schwartz, V. (2021) · BIOspektrum · doi:10.1007/s12268-021-1661-x
“Jahrgang frühen Phase der Medikamentenentwicklung verlangen die Zulassungsbehörden, das Risiko von Nebenwirkungen zu untersuchen, die für hohe Ausfallraten in klinischen Studien verantwortlich sind.”
BackgroundInfluentialTao, F., Hanada, S., Matsushima, K., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1285077/v1
Monterosso, M. E. (2022) · Queensland University of Technology · doi:10.5204/thesis.eprints.236375
How to reduce risk of drug induced liver toxicity from the beginning
Gan, J., He, K., & Humphreys, W. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-817134-9.00010-6 · Cited by 1
DILIrank dataset for QSAR modeling of drug-induced liver injury
Chen, M., Liao, T.-J., Li, D., Ning, B., Hong, H., & Tong, W. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15339-6.00014-x
New Alternative Methods in Drug Safety Assessment
Yang, X., Shi, Q., Chen, M., & Pang, L. (2023) · Springer eBooks · doi:10.1007/978-981-99-1284-1_14
Peptide-mimetic treatment of Pseudomonas aeruginosa in a mouse model of respiratory infectionPreprint
Moule, M. G., Benjamin, A. B., Buger, M. L., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.30.564794
Critical Care Nurses' Performance Regarding Management of Patients with Ventricular Arrhythmias
Ghareb, A. (2023) · Trends in Nursing and Health Care Journal · doi:10.21608/tnhcj.2023.218250.1018
High throughput production and characterization of primary rat hepatocyte spheroids
Gökaltun, A. (2024) · Hacettepe Journal of Biology and Chemistry · doi:10.15671/hjbc.1394326
Multi Organ Model Assessment of Neurotoxicity Following Exposure of Liver Spheroids to DrugsPreprint
Bein, A., Wu, W., Anas, F., Koc, B., Rezania, D., Sharareh, S., Farberov, L., Zlotnik, D., Alon, A., & Bentwich, I. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4789126
Advanced models to study liver sinusoids
Campinoti, S., Palma, E., Chokshi, S., & Urbani, L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95262-0.00007-3 · Cited by 2
Metabolism Studies In Vitro and In Vivo: An Editorial Update
Marker, A., Riedel, J., Dudda, A., & Kuerzel, G. U. (2024) · Springer eBooks · doi:10.1007/978-3-030-73317-9_109-1
Talari, A. C. S., Sbordoni, R., Hoti, V., Patel, I. I., Martin, F. L., Raza, A., & Llabjani, V. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.12.607396
“The assay was performed on day 2, 4, 7, 11, 14, 20, 26 and 31 according to the protocol provided by the vendor, on the same NS used for viability analysis.”
MethodMetabolism Studies In Vitro and In Vivo: An Editorial Update
Marker, A., Riedel, J., Dudda, A., & Kuerzel, G. U. (2024) · Springer eBooks · doi:10.1007/978-3-031-35529-5_109 · Cited by 1
Yoon, J., Song, H., Park, J. S., Kim, J. H., Jun, Y., Gim, S.-A., Hong, C., An, K. M., Park, J.-T., Lee, J. W., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117674 · Cited by 1
Λάμπρου, Μ., García, A. K., & Suijkerbuijk, S. J. E. (2025) · STAR Protocols · doi:10.1016/j.xpro.2024.103575 · Cited by 2
Non-Invasive Quantification of Viability in Spheroids Using Deep LearningPreprint
Dubinsky, D., Harel, S., Bein, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.09.642246
“Proctor et al. [8] introduce a method for DILI prediction using the biolumines-221 cent CellTiter-Glo(CTG) [5] assay for viability quantification.”
InfluentialTalari, A. C. S., Sbordoni, R., Hoti, V., Jalil, T., Patel, I. I., Martin, F. L., Raza, A., & Llabjani, V. (2025) · Research Square · doi:10.21203/rs.3.rs-6228265/v1
Talari, A. C. S., Sbordoni, R., Hoti, V., Jalil, T., Patel, I. I., Martin, F. L., Raza, A., & Llabjani, V. (2025) · In vitro models · doi:10.1007/s44164-025-00089-4 · Cited by 1
Bioactivation and reactivity research advances—2024 year in review
Liu, J., Argikar, U. A., Brunetti, P., Chatzopoulou, M., Chen, L., Cho, S., Hauri, S., Kramlinger, V. M., Lang, J., Ma, B., et al. (2025) · Drug Metabolism Reviews · doi:10.1080/03602532.2025.2530407
“It would be advantageous to employ longer incubation periods to better assess long-term toxicity, thereby providing a more comprehensive understanding of the potential risks associated with these compounds (Proctor et al. 2017).”
Metadata
- Authors
- Proctor, W. R., Foster, A. J., Vogt, J., Summers, C., Middleton, B., Pilling, M. A., Shienson, D., Kijanska, M., Ströbel, S., Kelm, J. M., Morgan, P., Messner, S., & Williams, D.
- Affiliations
- Genentech (US)
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Foster, Alison J.
- Venue
- Archives of Toxicology
- Published
- 2017-06-13
- Volume
- 91
- Issue
- 8
- Pages
- 2849-2863
- ISSN
- 0340-5761 (ISSN-L)
- 1432-0738
- PMC
- PMC5515971
- OpenAlex
- W2625311319
- Cited by
- 328
- References
- 52
- Citations by year
- 2026: 30 · 2025: 49 · 2024: 33 · 2023: 29 · 2022: 33 · 2021: 33 · 2020: 49 · 2019: 35 · 2018: 31 · 2017: 6
- FWCI
- 35.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Archives of Toxicology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- AstraZeneca
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- drug-induced liver injury, hepatotoxicity prediction, primary human hepatocytes, drug cytotoxicity, IC50, safety margin, liver injury biomarkers, miR-122, HMGB1, alpha-glutathione S-transferase
- MeSH terms
- Humans, Liver, Predictive Value of Tests, Time Factors, Drug Design, Biomarkers, Risk Assessment, Inhibitory Concentration 50, Hepatocytes, Drug Discovery, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.